Canaccord Genuity Initiates Coverage On Jazz Pharmaceuticals with Buy Rating, Announces Price Target of $290

Benzinga Newsdesk www.benzinga.com Neutral 61.5%

Neg 0% Neu 61.5% Pos 0%

Canaccord Genuity analyst Gary Nachman initiates coverage on Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy rating and announces Price Target of $290.